Epithelial IL-8 immunostaining associated with overall survival in ovarian cancer

Cytokines have major role in regulating the biological processes such as cell growth and activation, chemotaxis, inflammation, immunity and tissue repair. The cytokines involvement in oncogenesis shows their role in signaling between inflammatory cells and invasive neoplastic tissue. This study assessed the association of epithelial and stromal immunostaining of panel of cytokines with overall survival and disease-free survival in malignant ovarian neoplasia women. The study included 28 ovarian cancer patients. The patients’ age, staging, differentiation grade, histological type of tumors, treatment type and survivals (disease-free survival and overall survival) were evaluated. Immunohistochemical analysis was made to assess the epithelial and stromal immunostaining of interleukins (IL-2, IL-5, IL-6, IL-8, IL-10 and tumor necrosis factor alpha (TNF-α). Cut-off values for the immunostaining cytokines were calculated through Receiver operating characteristic (ROC) curves. Kaplan-Meier curves were designed to evaluate the survival followed by Cox regression. ROC curves relating death to epithelial IL-8 staining and stromal TNF-alpha staining exhibited a cut-off value more than staining 1 for both cytokines. There was no statistical significance found in the evaluation of other cytokines and disease-free survival. Overall survival was shorter in patients with epithelial IL-8 staining 2/3 (p = 0.049). No statistical significance was found regarding TNF-alpha stromal. Multivariate analysis revealed that epithelial IL-8 staining 2/3 was an independent variable linked to lower overall survival ((Odds ratio (OR) = 18.515. 95% confidence interval (CI): (1.160–295.549)). Therefore, epithelial IL-8 immunostaining predicts overall survival of ovarian malignancy patients. This cytokine can be the target for discovering other types of management systems for epithelial ovarian cancer and borderline ovarian tumor.

Ovarian neoplasms; Cytokines; Interleukin-8; Survival; Immunology

[1] The Global Cancer Observatory—World Health Organization. Ovary source: globocan 2020. 2020. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf (Accessed: 10 February 2023).

[2] INCA. Estimativa de Câncer no Brasil. 2020. Available at: https://www.inca.gov.br/publicacoes/livros/estimativa-2020-incidencia-de-cancer-no-brasil (Accessed: 10 February 2023).

[3] INCA. MS/INCA/Coordenação de Prevenção e Vigilância/Divisão de Vigilância e Análise de Situação. 2021. Available at: https://www.inca.gov.br/en/node/2244 (Accessed: 10 February 2023).

[4] Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nature Reviews Clinical Oncology. 2018; 15: 366–381.

[5] Hale MD, Hayden JD, Grabsch HI. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cellular Oncology. 2013; 36: 95–112.

[6] Sanguinete MMM, Oliveira PHD, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC, et al. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunological Investigations. 2017; 46: 677–688.

[7] Baghdadi M, Endo H, Takano A, Ishikawa K, Kameda Y, Wada H, et al. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Scientific Reports. 2018; 8: 418.

[8] Endo H, Hama N, Baghdadi M, Ishikawa K, Otsuka R, Wada H, et al. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression. International Immunology. 2020; 32: 175–186.

[9] Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research. 2011; 17: 6083–6096.

[10] Kim S, Gwak H, Kim HS, Kim B, Dhanasekaran DN, Song YS. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro. Oncotarget. 2016; 7: 83148–83159.

[11] Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, et al. Expression of B7–H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Human Pathology. 2021; 113: 20–27.

[12] Lin C, He H, Liu H, Li R, Chen Y, Qi Y, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019; 68: 1764–1773.

[13] Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. International Journal of Cancer. 2015; 136: 1504–1514.

[14] de Lima CA, Silva Rodrigues IS, Martins-Filho A, Côbo Micheli D, Martins Tavares-Murta B, Candido Murta EF, et al. Cytokines in peritoneal fluid of ovarian neoplasms. Journal of Obstetrics and Gynaecology. 2020; 40: 401–405.

[15] Rodrigues ISS, Martins-Filho A, Micheli DC, Lima CAD, Tavares-Murta BM, Murta EFC, et al. IL-6 and IL-8 as prognostic factors in peritoneal fluid of ovarian cancer. Immunological Investigations. 2020; 49: 510–521.

[16] Batchu RB, Gruzdyn OV, Kolli BK, Dachepalli R, Umar PS, Rai SK, et al. IL-10 signaling in the tumor microenvironment of ovarian cancer. Advances in Experimental Medicine and Biology. 2021; 1290: 51–65.

[17] Kumar P, Ranmale S, Tongaonkar H, Mania-Pramanik J. Immune profile of blood, tissue and peritoneal fluid: a comparative study in high grade serous epithelial ovarian cancer patients at interval debulking surgery. Vaccines. 2022; 10: 2121.

[18] Smycz-Kubańska M, Stępień S, Gola JM, Kruszniewska-Rajs C, Wendlocha D, Królewska-Daszczyńska P, et al. Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance. Molecular Medicine Reports. 2022; 26: 296.

[19] Micheli DC, Jammal MP, Martins-Filho A, Côrtes JRXDM, Souza CND, Nomelini RS, et al. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms. Biomarkers. 2020; 25: 474–482.

[20] Kampan NC, Kartikasari AER, Deceneux C, Madondo MT, McNally OM, Flanagan KL, et al. Combining TNFR2-expressing tregs and IL-6 as superior diagnostic biomarkers for high-grade serous ovarian cancer masses. Cancers. 2023; 15: 667.

[21] Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. The American Journal of Surgical Pathology. 2010; 34: 433–443.

[22] Kurman RJ, Shih I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Human Pathology. 2011; 42: 918–931.

[23] Spacek J, Vocka M, Netikova I, Skalova H, Dundr P, Konopasek B, et al. Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls. Immunological Investigations. 2018; 47: 643–653.

[24] Zuccari DAPDC, Leonel C, Castro R, Gelaleti GB, Jardim BV, Moscheta MG, et al. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochemica. 2012; 114: 571–576.

[25] Wen J, Zhao Z, Huang L, Wang L, Miao Y, Wu J. IL-8 promotes cell migration through regulating EMT by activating the Wnt/β‐catenin pathway in ovarian cancer. Journal of Cellular and Molecular Medicine. 2020; 24: 1588–1598.

[26] Uddin MM, Gaire B, Vancurova I. Interleukin-8 induces proliferation of ovarian cancer cells in 3D spheroids. Methods in Molecular Biology. 2020; 2108: 117–124.

[27] Ji Z, Tian W, Gao W, Zang R, Wang H, Yang G. Cancer-associated fibroblast-derived interleukin-8 promotes ovarian cancer cell stemness and malignancy through the notch3-mediated signaling. Frontiers in Cell and Developmental Biology. 2021; 9: 684505.

[28] Ade CJ, Dockery L, Walter AC, Benbrook DM, Vesely SK, Hammond ST, et al. Association between serum biomarkers with postoperative complications and delay of adjuvant chemotherapy initiation in ovarian cancer patients undergoing primary cytoreductive surgery: a pilot study. Nutrition and Cancer. 2023; 75: 662–669.

[29] Asschert JGW, Vellenga E, Ruiters MHJ, de Vries EGE. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. International Journal of Cancer. 1999; 82: 244–249.

[30] Sancéau J, Kaisho T, Hirano T, Wietzerbin J. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NFkB, and Sp1 transcription factors. Journal of Biological Chemistry. 1995; 270: 27920–27931.